Skip to main content
    N

    Neumora Therapeutics, Inc. (NMRA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.37
    -0.06 (-13.85%)

    Market Cap: $80.59M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Neumora Therapeutics, Inc. (NMRA) Earnings: Report Dates and Results

    Updated Aug 14, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Neumora Therapeutics (NMRA) is expected to report earnings on Nov 19, 2026. In the quarter ended Jun 30, 2026, Neumora Therapeutics reported EPS of -$0.23, in line with the -$0.23 estimate. It beat the EPS estimate in 5 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    42%(5/12)
    Avg Surprise
    -13.37%

    Upcoming Estimates

    Report date not yet scheduledPeriod ending Dec 31, 2026
    EPS Consensus-$0.18
    Range-$0.20 - -$0.14
    10 analysts
    Revenue Consensus
    N/A
    RangeN/A
    10 analysts

    Next Report

    NMRA has an expected report date of Nov 19, 2026.

    NMRA Earnings Call

    The latest NMRA earnings call transcript on file is labeled 2025Q4.

    Read the 2025Q4 transcript

    Earnings History

    Of the 12 quarters below that had an estimate, NMRA beat 5, missed 6 and matched 1. The widest gap in the table came in the quarter ended Sep 30, 2023, when EPS landed 165.12% below the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReported
    Jun 30, 2026-$0.23-$0.23-$0.30 - -$0.200.00%In lineN/A90 up, 1 downAug 14, 2026
    Mar 31, 2026-$0.30-$0.31-$0.36 - -$0.26+3.23%BeatN/A72 up, 1 downMay 7, 2026
    Dec 31, 2025-$0.35-$0.47N/A+25.53%BeatN/A81 up, 2 downMar 16, 2026
    Sep 30, 2025-$0.35-$0.34-$0.39 - -$0.28-2.94%MissN/A60 up, 1 downNov 6, 2025
    Jun 30, 2025-$0.33-$0.37-$0.44 - -$0.33+10.81%BeatN/A74 up, 1 downAug 6, 2025
    Mar 31, 2025-$0.42-$0.46-$0.46 - -$0.34+8.70%BeatN/A63 up, 0 downMay 12, 2025
    Dec 31, 2024-$0.37-$0.44-$0.47 - -$0.40+15.91%BeatN/A60 up, 0 downMar 3, 2025
    Sep 30, 2024-$0.45-$0.38-$0.43 - -$0.33-18.42%MissN/A80 up, 1 downNov 12, 2024
    Jun 30, 2024-$0.37-$0.36-$0.41 - -$0.34-2.78%MissN/A70 up, 0 downAug 6, 2024
    Mar 31, 2024-$0.34-$0.32-$0.40 - -$0.32-6.25%MissN/A51 up, 0 downMay 7, 2024
    Dec 31, 2023-$0.71-$0.55-$1.52 - -$0.31-29.09%MissN/A60 up, 0 downMar 7, 2024
    Sep 30, 2023-$1.14-$0.43N/A-165.12%MissN/AN/AN/ANov 1, 2023
    Jun 30, 2023-$0.28N/AN/AN/AN/AN/AN/AN/AAug 30, 2023
    Last 13 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$1.45, after -$1.53 the year before. It was -$2.13 for the year ended Dec 31, 2023, the oldest of the 3 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$1.45N/A
    Dec 31, 2024-$1.53N/A
    Dec 31, 2023-$2.13N/A

    Earnings Calls

    The 5 most recent earnings calls are listed below; the latest, 2025Q4 for the period ended Dec 31, 2025, runs about 5,600 words across 15 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2025Q4Dec 31, 20255,58215
    2025Q2Jun 30, 20254,41012
    2025Q1Mar 31, 20254,09911
    2024Q4Dec 31, 20245,06513
    2024Q3Sep 30, 20243,40012

    2025Q4 Earnings Call

    Opening remarks

    Helen Rubinstein Vice President, Investor Relations and Corporate Strategy Good afternoon, and thank you for joining Neumora Therapeutics Fourth Quarter and Full Year 2025 Financial Results Conference Call. Before we begin, I encourage everyone to visit the Investors and Media section of our website at neumoratx.com, where you can find the press release related to today's call. With me on the call today are Chief Executive Officer, Paul Berns; President, Josh Pinto; Chief Operating and Development Officer, Bill Aurora; Chief Scientific Officer, Nick Brandon; and Chief Financial Officer, Mike Milligan. I'd like to point out that we will be making forward-looking statements during today's call, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. Please review the risk factors discussed in today's press release and in our SEC filings for additional detail. With that, I'll now turn the call over to Paul.

    Paul Berns Chief Executive Officer Thanks, Helen. Good morning, everyone, and thank you for joining us. 2025 marked a year of important clinical progress and execution for Neumora. We made meaningful strides in advancing our diverse pipeline of novel mechanism therapies, reported compelling data for NMRA-511, our oral highly potent brain-penetrant and selective vasopressin 1a receptor antagonist, progressed our Phase III program for navacaprant with optimizations based on key learnings from prior studies, expanded our M4 PAM franchise with two new programs in clinical development and prioritized obesity as the lead indication for our brain-penetrant NLRP3 inhibitor, NMRA-215 and reported class-leading DIO data, all while continuing to strengthen our financial foundation. Our mission at Neumora remains clear: to advance the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients living with brain diseases. We believe through our differentiated approach centered on advancing programs with best-in-class pharmacology and brain-penetrant chemistry targeting novel mechanisms of action, we have the potential to deliver transformative therapies to millions of patients in need of better options. Now as we move into 2026, Neumora is well positioned to achieve multiple potentially value-creating milestones within the next 12 months. As we approach these near-term catalysts, I am confident in the strength of our science, the focus of our strategy and the dedication of our distinguished Neumora team to deliver revolutionized therapies for patients living with brain diseases. I will now turn the call over to Josh to review our pipeline updates. Josh?

    Joshua Pinto President Thank you, Paul. We are poised to build on the strong momentum from 2025 as we enter a catalyst-rich period with multiple clinical data readouts expected this year. Leading with NMRA-511, our oral highly potent brain-penetrant and selective antagonist of the vasopressin 1a receptor in Alzheimer's disease agitation.

    Frequently Asked Questions About NMRA

    When is Neumora Therapeutics's next earnings date?

    Neumora Therapeutics's next earnings report is expected for Nov 19, 2026.

    Did NMRA beat earnings estimates last quarter?

    Neumora Therapeutics reported EPS of -$0.23 for the quarter ended Jun 30, 2026, in line with the -$0.23 estimate.

    What EPS do analysts expect from NMRA next quarter?

    The consensus EPS estimate for Neumora Therapeutics for the quarter ending Dec 31, 2026 is -$0.18 from 10 analysts, with estimates from -$0.20 to -$0.14.

    How often does NMRA beat earnings estimates?

    Neumora Therapeutics beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +5.35%.